The pharmacokinetics of chelerythrine solution and chelerythrine liposomes after oral administration to rats

Planta Medica

Volumn 79, Issue 8, 2013, Pages 654-660

  Li, Weifeng ^a   Xing, Wei ^a   Niu, Xiaofeng ^a   Zhou, Ping ^a   Fan, Ting ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

chelerythrine; emulsion solvent evaporation; liposome; pharmacokinetics

Indexed keywords

CHELERYTHRINE; DIHYDROCHELERYTHRINE; DRUG METABOLITE; LIPOSOME; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; EMULSION; EVAPORATION; HYDROPHILICITY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; BENZOPHENANTHRIDINES; LIPOSOMES; MICROSCOPY, ELECTRON; PARTICLE SIZE; RATS; SOLUTIONS;

RATTUS;

EID: 84878229354     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0032-1328540     Document Type: Article

References (23)

1. The pharmacopoeia of the peoples Republic of China. Part II. Beijing The Pharmacopoeia Commission of PRC: 2010
2. Mazzanti G., Di Sotto A., Franchitto A., Mammola C. L., Mariani P., Mastrangelo S., Menniti-Ippolito F., Vitalone A. Chelidonium majus is not hepatotoxic in Wistar rats, in a 4 weeks feeding experiment. J Ethnopharmacol: 2009; 126 518 524
3. Niu X. F., Zhou P., Li W. F., Xu H. B. Effects of chelerythrine, a specific inhibitor of cyclooxygenase-2, on acute inflammation in mice. Fitoterapia: 2011; 82 620 625
4. Kosina P., Vacek J., Papoušková B., Stiborová M., Stýskala J., Cankař P., Vrublová E., Vostá lová J., Simánek V., Ulrichová J. Identification of benzo[c]phenanthridine metabolites in human hepatocytes by liquid chromatography with electrospray ion-trap and quadrupole time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci: 2011; 879 1077 1085
5. Vecera R., Klejdus B., Kosina P., Orolin J., Stiborová M., Smrcek S., Vicar J., Dvorák Z., Ulrichová J., Kubán V., Anzenbacher P., Simánek V. Disposition of sanguinarine in the rat. Xenobiotica: 2007; 37 549 558 (Pubitemid 46823440)
6. Vacek J., Vrublová E., Kubala M., Janovská M., Fojta M., Šimková E., Stýskala J., Skopalová J., Hrbáč J., Ulrichová J. Oxidation of sanguinarine and its dihydro-derivative at a pyrolytic graphite electrode using Ex Situ Voltammetry. Study of the interactions of the alkaloids with DNA. Electroanalysis: 2011; 23 1671 1680
7. Vrublova E., Vostalova J., Vecera R., Klejdus B., Stejskal D., Kosina P., Zdarilova A., Svobodova A., Lichnovsky V., Anzenbacher P., Dvorak Z., Vicar J., Simanek V., Ulrichova J. The toxicity and pharmacokinetics of dihydrosanguinarine in rat: A pilot study. Food Chem Toxicol: 2008; 46 2546 2553
8. Pison U., Welte T., Giersig D. A., Groneberg M. Nanomedicine for respiratory diseases. Eur J Pharmacol: 2006; 533 341 350 (Pubitemid 43340025)
9. Torchilin V. P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov: 2005; 4 145 160 (Pubitemid 40282557)
10. Chen L. C., Wu Y. H., Liu I. H., Ho C. L., Lee W. C., Chang C. H., Lan K. L., Ting G., Lee T. W., Shien J. H. Pharmacokinetics, dosimetry and comparative efficacy of (188)Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model. Nucl Med Biol: 2012; 39 35 43
11. Mukherjee S., Ray S., Thakur R. S. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci: 2009; 71 349 358
12. Mehnert W., Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev: 2001; 47 165 196 (Pubitemid 32324113)
13. Li Q., Jia Y., Sun L. X., Xu L., Tong L., Shen Z. D., Liu Y. L., Bi K. S. High-performance liquid chromatographic determination of isofraxidin in rat plasma. Chromatographia: 2006; 63 249 253
14. Liu D. F., Jiang S. M., Shen H., Qin S., Liu J. J., Zhang Q., Li R., Xu Q. W. Diclofenac sodium-loaded solid lipid nanoparticles prepared by emulsion/solvent evaporation method. J Nanopart Res: 2011; 13 2375 2386
15. Reddy L. H., Vivek K., Bakshi N., Murthy R. S. Tamoxifen citrate loaded solid lipid nanoparticles (SLN): preparation, characterization, in vitro drug release, and pharmacokinetic evaluation. Pharm Dev Technol: 2006; 11 167 177 (Pubitemid 43879940)
16. Liu J., Hu W., Chen H., Ni Q., Xu H., Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm: 2007; 328 191 195 (Pubitemid 44880576)
17. Zhang X., Lu S., Han J., Sun S., Wang L., Li Y. Preparation, characterization and in vivo distribution of solid lipid nanoparticles loaded with syringopicroside. Pharmazie: 2011; 66 404 407
18. China S. FDA. Technical guideline on non-clinical pharmacokinetic studies, 2005. Available at. http://www.sfda.com Accessed 2012
19. Gao S. H., Fan G. R., Hong Z. Y., Yin X. P., Yang S. L., Wu Y. T. HPLC determination of polydatin in rat biological matrices: application to pharmacokinetic studies. J Pharm Biomed Anal: 2006; 41 240 245
20. Suresh G., Manjunath K., Venkateswarlu V., Satyanarayana V. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS Pharm Sci Technol: 2007; 8 162 170
21. Zhang J., Fan Y., Smith E. Experimental design for the optimization of lipid nanoparticles. J Pharm Sci: 2009; 98 1813 1819
22. Anton N., Benoit J. P., Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates-a review. J Control Release: 2008; 128 185 199
23. Das S., Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS Pharm Sci Technol: 2011; 12 62 76